N-acetylcysteine in Bulimia Nervosa

Status

Terminated

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01131572

Enrollment

Registered

2010-05-27

Start date

2010-02-28

Completion date

2012-03-31

Last updated

2013-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAC

Brief summary

This study tests NAC in the treatment of Bulimia Nervosa.

Interventions

DRUGN-acetylcysteine NAC

N-acetylcysteine in the treatment of Bulimia Nervosa

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Bulimia Nervosa * 18-65 years of age

Design outcomes

Primary

Measure	Time frame	Description
Binge-purge episodes	per week	The primary outcome measure will be the weekly frequency of binge-purge episodes. A binge-purge eating episode will be defined using DSM-IV-TR criteria, and accessed via clinical interview and review of subject take-home diaries at each study visit.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026